Cost-benefit and efficacy of aprotinin compared with ε-aminocaproic acid in patients having repeated cardiac operations: A randomized, blinded clinical trial

Anesthesiology

Volumn 87, Issue 6, 1997, Pages 1373-1380

  Bennett Guerrero, Elliott ^a   Sorohan, Jonathan G ^b   Gurevich, Miguel L ^b   Kazanjian, Paul E ^b   Levy, Roberto R ^b   Barberá, Alberto V ^b   White, William D ^b   Slaughter, Thomas F ^b   Sladen, Robert N ^b   Smith, Peter K ^b   Newman, Mark F ^b  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b NONE

Author keywords

aminocaproic acid; Aprotinin; Coagulation; Complications: bleeding; Cost benefit analysis; Fibrinolysis; Surgery: cardiac

Indexed keywords

AMINOCAPROIC ACID; APROTININ;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG COST; DRUG EFFICACY; ERYTHROCYTE TRANSFUSION; FEMALE; HEART SURGERY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PEROPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; THORAX DRAINAGE; THROMBOCYTE TRANSFUSION;

6-AMINOCAPROIC ACID; ADULT; AGED; ANTIFIBRINOLYTIC AGENTS; APROTININ; BLOOD LOSS, SURGICAL; CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; COST-BENEFIT ANALYSIS; DRUG EVALUATION; FEMALE; HEART VALVES; HEMOSTATICS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REOPERATION; SINGLE-BLIND METHOD;

EID: 0031437079     PISSN: 00033022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000542-199712000-00017     Document Type: Article

References (41)

1. National Center for Health Statistics. (DHHS publication no. [PHS] 95-1782). Vital and Health Statistics, Series 13. Hyattsville, MD, Department of Health and Human Services, 1995
2. Ferraris VA, Ferraris SP: Limiting excessive postoperative blood transfusion after cardiac procedures. Tex Heart Inst J 1995; 22:216-30
3. Jobes DR, Ellison N: Hemotherapy: Control of hemostasis and blood replacement, Cardiac Anesthesia: Principles and Clinical Practice. Edited by FG Estafanous, PG Barash, JG Reves. Philadelphia, JB Lippincott, 1994, pp 597-620
4. Wallace EL, Churchill WH, Surgenor DM, Cho G, McGurk S, Murphy L: Collection and transfusion of blood and blood components in the United States, 1992. Transfusion 1995; 35:802-12
5. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ: The risk of transfusion-transmitted viral infections. N Engl J Med 1996; 334:1685-90
6. Landers DL, Hill GE, Wong KC, Fox IJ: Blood transfusion-induced immunomodulation. Anesth Analg 1996; 82:187-204
7. Graves EJ: National hospital discharge survey: Annual summary, 1991. Vital Health Stat 1993; 114:1-62
8. Royston D: High dose aprotinin therapy: A review of the first five years experience. J Cardiothorac Vase Anesth 1992; 6:76-100
9. Cosgrove DM, Heric B, Lytle BW, Taylor PC, Novoa R, Golding LA, Stewart RW, McCarthy PM, Loop FD: Aprotinin therapy for reoperative myocardial revascularization: A placebo-controlled study. Ann Thorac Surg 1992; 54:1031-8
10. Lemmer JH, Stanford W, Bonney SL, Breen JF, Chomka EV, Eldredge WJ, Holt WW, Karp RB, Laub GW, Lipton MJ, Schaff HV, Tatooles CJ, Rumberger JA: Aprotinin for coronary bypass operations-efficacy, safety, and influence on early saphenous vein graft patency - A multicenter, randomized, double-blind, placebo-controlled study. J Thorac Cardiovasc Surg 1994; 107:543-53
11. Levy JH, Pifarre R, Schaff HV, Horrow JC, Albus R, Spiess B, Rosengart TK, Murray J, Clark RE, Smith P: A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation 1995; 92:2236-44
12. Vander Salm TJ, Kaur S, Lancey RA, Okike ON, Pezzella AT, Stahl RF, Leone L, Li JM, Valeri CR, Michelson AD: Reduction of bleeding after heart operations through the prophylactic use of epsilon-aminocaproic acid. J Thorac Cardiovasc Surg 1996; 112:1098-107
13. van Oeveren W, Harder MP, Roozendaal KJ, Eijsman L, Wildevuur CRH: Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990; 99:788-97
14. Ammar T, Saner K, Vela-Cantos F: The effects of aprotinin and tranexamic acid on the platelet membrane GPIb receptor [Abstract]. ANESTHESIOLOGY 1996; 85:A146
15. Orchard MA, Goodchild CS, Prentice CRM, Davies JA, Benoit SE, Creighton-Kemsford LJ, Gaffney PJ, Michaelson AD: Aprotinin reduces cardiopulmonary bypass-induced blood loss and inhibits fibrinolysis without influencing platelets. Br J Haematol 1993; 85:533-41
16. Huang H, Ding W, Su Z, Zhang W: Mechanism of the preserving effect of aprotinin on platelet function and its use in cardiac surgery. J Thorac Cardiovasc Surg 1993; 106:11-8
17. Adelman B, Michelson AD, Loscalzo J, Greenberg J, Handin RI: Plasmin effect on platelet glycoprotein Ib-von Willebrand factor interactions. Blood 1985; 65:32-40
18. Fremes SE, Wong BI, Lee E, Mai R, Christakis GT, McLean RF, Goldman BS, Naylor CD: Metaanalysis of prophylactic drug treatment in the prevention of postoperative bleeding. Ann Thorac Surg 1994; 58:1580-8
19. Cardinale V: 1996 red book: Pharmacy's fundamental reference. Montvale, NJ, Medical Economics Data, 1996
20. Ward ME: Estimation of capitation expense for specialty services. Ann Thorac Surg 1996; 62:S26-30
21. Daily PO, Lamphere JA, Dembitsky WP, Adamson RM, Dans NE: Effect of prophylactic epsilon-aminocaproic acid on blood loss and transfusion requirements in patients undergoing first-time coronary artery bypass grafting: A randomized, prospective, double-blind study. J. Thorac Cardiovasc Surg 1994; 108:99-108
22. Arom KV, Emery RW: Decreased postoperative drainage with addition of epsilon-aminocaproic acid before cardiopulmonary bypass. Ann Thorac Surg 1994; 57:1108-13
23. Alderman EL: Angiographic correlates of graft patency and relationship to clinical outcomes. Ann Thorac Surg 1996; 62:S22-55
24. Diefenbach C, Abel M, Limpers B, Lynch J, Ruskowski H, Jugert FK, Buzello W: Fatal anaphylactic shock after aprotinin reexposure in cardiac surgery. Anesth Analg 1995; 80:830-1
25. Lubarsky DA, Hahn C, Bennett DH, Smith LR, Bredehoeft SJ, Klein HG, Reves JG: The hospital cost (fiscal year 1991/1992) of a simple perioperative allogeneic red blood cell transfusion during elective surgery at Duke University. Anesth Analg 1994; 79:629-37
26. Etchason J, Petz L, Keeler E, Calhoun L, Kleinman S, Snider C, Fink A, Brook R: The cost effectiveness of preoperative autologous blood donations. N Engl J Med 1995; 332:719-24
27. Gan TJ, Lubarsky D, Robertson K, Bennett D, Parillo S, Sanderson I, Jhaveri R: The hospital cost of perioperative transfusion of a unit of red blood cells and other blood products [Abstract]. Anesth Analg 1996; 82:S123
28. Traverso LW, Hargrave K: A prospective cost analysis of laparascopic cholecystectomy. Am J Surg 1995; 169:503-6
29. Blauhut B, Harringer W, Bettelheim P, Doran JE, Spath P, Lundsgaard-Hansen P: Comparison of the effects of aprotinin and tranexamic acid on blood loss and related variables after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1994; 108:1083-91
30. Menichetti A, Tritapepe L, Ruvolo G, Speziale G, Cogliati A, DiGiovanni, Pacilli M, Criniti A: Changes in coagulation patterns, blood loss and blood use after cardiopulmonary bypass: aprotinin vs tranexamic acid vs epsilon aminocaproic acid. J Cardiovasc Surg 1996; 37:401-7
31. Speekenbrink RGH, Vonk ABA, Wildevuur CRH, Eijsman L: Hemostatic efficacy of dipyridamole, tranexamic acid, and aprotinin in coronary artery bypass grafting. Ann Thorac Surg 1995; 59:438-42
32. Newman RJ, Podolsky D, Loeb P: Bad blood. U.S. News and World Report 1994; June 27:68-78
33. Trinh-Duc P, Wintrebert P, Boulfroy D, Albat B, Thevenet A, Roquefeuil B: Comparison des effets de l'acide E-aminocaproique et de l'aprotinine sur le saignement per- et post-operatoire en chirurgie cardiaque. Ann Chir Thorac Cardiovasc 1992; 46:677-83
34. Penta de Peppo A, Danilo Pierri M, Scafuri A, DePaulis R, Colantuono G, Caprara E, Tomai F, Chiariello L: Intraoperative antifibrinolysis and blood-saving techniques in cardiac surgery: Prospective trial of 3 antifibrinolytic drugs. Tex Heart Inst J 1995; 22:231-6
35. Pugh SC, Wielogorski AK: A comparison of the effects of tranexamic acid and low-dose aprotinin on blood loss and homologous blood usage in patients undergoing cardiac surgery. J Cardiothorac Vase Anesth 1995; 9:240-4
36. Boughenou F, Madi-Jebara S, Massonnet-Castel S, Benmosbah L, Carpentier A, Cousin MT: Antifibrinolytiques et prévention du saignement en chirurgie cardiaque valvulaire: Comparison de l'acide tranexamique à l'aprotinine à haute dose. Arch Mal Coeur Vaiss 1995; 88:363-70
37. Package insert. Aprotinin (Trasylol®). West Haven, CT, Bayer Corporation Pharmaceutical Division
38. Hardy JF, Desroches J, Belisle S, Perrault J, Carrier M, Robitaille D: Low-dose aprotinin is not clinically useful to reduce bleeding and transfusion of homologous blood products in high-risk cardiac surgical patients. Can J Anaesth 1993; 40:625-31
39. Schöpf K, Dietrich W, Spannagl M, Richter JA: High aprotinin dosage is more effective in preserving hemostasis and reducing blood loss in cardiac surgery than low dosage [Abstract]. Anesth Analg 1995; 80:125
40. Covino E, Pepino P, Iorio D, Marino L, Ferrara P, Spampinato N: Low dose aprotinin as blood saver in open heart surgery. Eur J Cardiothorac Surg 1991; 5:414-8
41. Weber C, Kalmar P, Pokar H: Safety and efficacy of aprotinin in open heart surgery: Dose comparison study of full vs. half Hammersmith-dosage [Abstract]. Anesth Analg 1995; 80:117